NO172585B - Analogifremgangsmaate for fremstilling av farmasoeytisk aktive fosfino-hydrocarbon-gruppe viii-metallkomplekser - Google Patents

Analogifremgangsmaate for fremstilling av farmasoeytisk aktive fosfino-hydrocarbon-gruppe viii-metallkomplekser Download PDF

Info

Publication number: NO172585B
Authority: NO; Norway
Prior art keywords: bis; diphenylphosphino; sub; preparation; compound
Prior art date: 1985-10-25

Application number

NO864270A

Other languages

English (en)

Norwegian (no)

Other versions

NO864270D0 (no

NO864270L (no

Inventor

Klaas Timmer

Harmen Anne Meinema

John Eberhard Schurig

Original Assignee

Tno

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-25

Filing date

1986-10-24

Publication date

1993-05-03

1986-10-24 Application filed by Tno filed Critical Tno

1986-10-24 Publication of NO864270D0 publication Critical patent/NO864270D0/no

1987-04-27 Publication of NO864270L publication Critical patent/NO864270L/no

1993-05-03 Publication of NO172585B publication Critical patent/NO172585B/no

Links

238000000034 method Methods 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims description 13
229910052751 metal Inorganic materials 0.000 title description 7
239000002184 metal Substances 0.000 title description 7
150000001875 compounds Chemical class 0.000 claims abstract description 29
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims abstract description 8
QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims description 11
-1 perchlorate compound Chemical class 0.000 claims description 7
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 6
NIPPJMSKAOITEK-UHFFFAOYSA-N 2-diphenylarsanylethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CC[As](C=1C=CC=CC=1)C1=CC=CC=C1 NIPPJMSKAOITEK-UHFFFAOYSA-N 0.000 claims description 5
FAFGMAGIYHHRKN-UHFFFAOYSA-N 2-diphenylphosphanylethyl(diphenyl)phosphane;palladium Chemical compound [Pd].C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 FAFGMAGIYHHRKN-UHFFFAOYSA-N 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
229910021607 Silver chloride Inorganic materials 0.000 claims description 3
239000004323 potassium nitrate Substances 0.000 claims description 3
235000010333 potassium nitrate Nutrition 0.000 claims description 3
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 3
QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 claims description 3
VYXHVRARDIDEHS-QGTKBVGQSA-N (1z,5z)-cycloocta-1,5-diene Chemical compound C\1C\C=C/CC\C=C/1 VYXHVRARDIDEHS-QGTKBVGQSA-N 0.000 claims description 2
239000007795 chemical reaction product Substances 0.000 claims description 2
239000000539 dimer Substances 0.000 claims description 2
239000004215 Carbon black (E152) Substances 0.000 abstract description 7
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 abstract description 5
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 abstract description 2
229910002651 NO3 Inorganic materials 0.000 abstract description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract description 2
XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical group [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 abstract description 2
230000002401 inhibitory effect Effects 0.000 abstract description 2
150000002736 metal compounds Chemical class 0.000 abstract description 2
230000004565 tumor cell growth Effects 0.000 abstract description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 2
229910052698 phosphorus Inorganic materials 0.000 abstract 2
239000011574 phosphorus Substances 0.000 abstract 2
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical group [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 abstract 1
229910052785 arsenic Inorganic materials 0.000 abstract 1
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 abstract 1
150000004820 halides Chemical class 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
229930195733 hydrocarbon Natural products 0.000 abstract 1
150000002430 hydrocarbons Chemical class 0.000 abstract 1
MILUBEOXRNEUHS-UHFFFAOYSA-N iridium(3+) Chemical compound [Ir+3] MILUBEOXRNEUHS-UHFFFAOYSA-N 0.000 abstract 1
WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
230000000259 anti-tumor effect Effects 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
230000000694 effects Effects 0.000 description 12
241000699670 Mus sp. Species 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
239000000725 suspension Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
208000032839 leukemia Diseases 0.000 description 8
238000003756 stirring Methods 0.000 description 8
239000000047 product Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
241001529936 Murinae Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
238000009835 boiling Methods 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
229960004316 cisplatin Drugs 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003797 essential amino acid Substances 0.000 description 3
235000020776 essential amino acid Nutrition 0.000 description 3
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
239000007858 starting material Substances 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
208000001382 Experimental Melanoma Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
NCKJIJSEWKIXAT-QURGRASLSA-N [(e)-2-diphenylphosphanylethenyl]-diphenylphosphane Chemical group C=1C=CC=CC=1P(C=1C=CC=CC=1)/C=C/P(C=1C=CC=CC=1)C1=CC=CC=C1 NCKJIJSEWKIXAT-QURGRASLSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
238000001816 cooling Methods 0.000 description 2
150000004696 coordination complex Chemical class 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000011835 investigation Methods 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
229940054269 sodium pyruvate Drugs 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
UEFOAOSSGNBDOD-UHFFFAOYSA-N 2-diphenylphosphanylethyl(diphenyl)phosphane nickel(2+) dinitrate Chemical compound [Ni+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 UEFOAOSSGNBDOD-UHFFFAOYSA-N 0.000 description 1
VGZQMZRKQWICJF-UHFFFAOYSA-L 2-diphenylphosphanylethyl(diphenyl)phosphane nickel(2+) diperchlorate Chemical compound [Ni+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 VGZQMZRKQWICJF-UHFFFAOYSA-L 0.000 description 1
ZAAWXKZFQQMGIX-UHFFFAOYSA-K 2-diphenylphosphanylethyl(diphenyl)phosphane;trichlororhodium Chemical compound Cl[Rh](Cl)Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 ZAAWXKZFQQMGIX-UHFFFAOYSA-K 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
229910021604 Rhodium(III) chloride Inorganic materials 0.000 description 1
HCFYRCFGZZIACS-UHFFFAOYSA-N [Cu+].[Cu+].C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)P(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)P(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)P(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound [Cu+].[Cu+].C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)P(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)P(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)P(C=1C=CC=CC=1)C1=CC=CC=C1 HCFYRCFGZZIACS-UHFFFAOYSA-N 0.000 description 1
WLMOAHYOHOSOHO-UHFFFAOYSA-N [Ir+].C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical class [Ir+].C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 WLMOAHYOHOSOHO-UHFFFAOYSA-N 0.000 description 1
NPYSLKQMBBQALU-UHFFFAOYSA-M [Ir]Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound [Ir]Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 NPYSLKQMBBQALU-UHFFFAOYSA-M 0.000 description 1
YFPUSLTXUGMXLL-UHFFFAOYSA-M [Rh]Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound [Rh]Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 YFPUSLTXUGMXLL-UHFFFAOYSA-M 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
RBYGDVHOECIAFC-UHFFFAOYSA-L acetonitrile;palladium(2+);dichloride Chemical compound [Cl-].[Cl-].[Pd+2].CC#N.CC#N RBYGDVHOECIAFC-UHFFFAOYSA-L 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940045985 antineoplastic platinum compound Drugs 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
UMWYYMCOBYVEPY-UHFFFAOYSA-N azanide;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2] UMWYYMCOBYVEPY-UHFFFAOYSA-N 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
XTEGARKTQYYJKE-UHFFFAOYSA-M chlorate Inorganic materials [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
UIBPVOHCUYIKFM-UHFFFAOYSA-N cobalt(2+) 2-diphenylphosphanylethyl(diphenyl)phosphane Chemical class [Co+2].C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 UIBPVOHCUYIKFM-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
FYWYMUFSLOEHHJ-UHFFFAOYSA-L dibromocobalt;2-diphenylphosphanylethyl(diphenyl)phosphane Chemical compound Br[Co]Br.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 FYWYMUFSLOEHHJ-UHFFFAOYSA-L 0.000 description 1
KETAVDRXXNKYKF-UHFFFAOYSA-L dichlorocobalt;2-diphenylphosphanylethyl(diphenyl)phosphane Chemical compound Cl[Co]Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 KETAVDRXXNKYKF-UHFFFAOYSA-L 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000834 fixative Substances 0.000 description 1
ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical class [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003058 platinum compounds Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229960001153 serine Drugs 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
IXGNPUSUVRTQGW-UHFFFAOYSA-M sodium;perchlorate;hydrate Chemical compound O.[Na+].[O-]Cl(=O)(=O)=O IXGNPUSUVRTQGW-UHFFFAOYSA-M 0.000 description 1
239000000126 substance Substances 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
TYLYVJBCMQFRCB-UHFFFAOYSA-K trichlororhodium;trihydrate Chemical compound O.O.O.[Cl-].[Cl-].[Cl-].[Rh+3] TYLYVJBCMQFRCB-UHFFFAOYSA-K 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
- C07F15/004—Iridium compounds without a metal-carbon linkage
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/006—Palladium compounds
- C07F15/0066—Palladium compounds without a metal-carbon linkage
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
- C07F15/008—Rhodium compounds without a metal-carbon linkage
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/04—Nickel compounds
- C07F15/045—Nickel compounds without a metal-carbon linkage
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/06—Cobalt compounds
- C07F15/065—Cobalt compounds without a metal-carbon linkage

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO864270A 1985-10-25 1986-10-24 Analogifremgangsmaate for fremstilling av farmasoeytisk aktive fosfino-hydrocarbon-gruppe viii-metallkomplekser NO172585B (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NL8502929A NL8502929A (nl)	1985-10-25	1985-10-25	Groep viii-overgangsmetaal-complexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een geneesmiddel met toepassing van een dergelijke groep viii-overgangsmetaal-complex voor de behandeling van kanker, alsmede aldus verkregen gevormd geneesmiddel.

Publications (3)

Publication Number	Publication Date
NO864270D0 NO864270D0 (no)	1986-10-24
NO864270L NO864270L (no)	1987-04-27
NO172585B true NO172585B (no)	1993-05-03

Family

ID=19846766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO864270A NO172585B (no)	1985-10-25	1986-10-24	Analogifremgangsmaate for fremstilling av farmasoeytisk aktive fosfino-hydrocarbon-gruppe viii-metallkomplekser

Country Status (21)

Country	Link
US (1)	US4831170A (da)
EP (1)	EP0227127B1 (da)
JP (1)	JPS62161795A (da)
KR (1)	KR870003787A (da)
CN (3)	CN86107219A (da)
AT (1)	ATE63122T1 (da)
AU (1)	AU601954B2 (da)
CA (1)	CA1269395A (da)
DE (1)	DE3679045D1 (da)
DK (1)	DK511786A (da)
ES (1)	ES2039199T3 (da)
FI (1)	FI85861C (da)
GR (1)	GR3001910T3 (da)
HU (2)	HU203557B (da)
IL (1)	IL80416A0 (da)
NL (1)	NL8502929A (da)
NO (1)	NO172585B (da)
NZ (1)	NZ218072A (da)
PT (1)	PT83612B (da)
YU (1)	YU45802B (da)
ZA (1)	ZA868162B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1282218A (zh) *	1997-10-15	2001-01-31	波拉克斯生物药品	使用砷化合物治疗原发性及转移性肿瘤疾病的组合物及方法
JP5015451B2 (ja) *	2005-04-18	2012-08-29	日本化学工業株式会社	ホスフィン遷移金属錯体、その製造方法およびそれを含有する抗癌剤
WO2009081366A1 (en) *	2007-12-20	2009-07-02	Richard John Bowen	Palladium and platinum phosphine complexes and their use as anti-tumour agents
WO2009104167A1 (en) *	2008-02-22	2009-08-27	Mintek	A substance or composition for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3084179A (en) *	1959-02-27	1963-04-02	Ici Ltd	Phosphorous-containing-ligand stabilized transition metal compounds
US3345392A (en) *	1964-03-24	1967-10-03	American Cyanamid Co	Organophosphorus-copper complex compounds
GB1085762A (en) *	1965-04-30	1967-10-04	Ici Ltd	Complex organic iridium compounds and their use as catalysts
FR2116905A5 (fr) *	1970-12-10	1972-07-21	Inst Francais Du Petrole	Nouveaux coordinats bidentes,leur fabrication et leurs applications
US3939188A (en) *	1972-03-24	1976-02-17	Exxon Research And Engineering Company	Preparation of zerovalent phosphine substituted rhodium compounds and their use in the selective carbonylation of olefins
US3954821A (en) *	1975-06-30	1976-05-04	E. I. Du Pont De Nemours And Company	Carbon dioxide complexes of Rh, Ir, Ni, Pd, and Pt
US4268454A (en) *	1978-12-21	1981-05-19	Allied Chemical Corporation	Anionic group VIII metal hydride catalysts
US4302401A (en) *	1980-01-23	1981-11-24	Exxon Research & Engineering Co.	Tetraalkyl phosphonium substituted phosphine and amine transition metal complexes
US4331818A (en) *	1980-03-19	1982-05-25	The Procter & Gamble Company	Chiral phospine ligand
CA1238854A (en) *	1984-02-01	1988-07-05	David T. Hill	ANTITUMOR PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUMORS EMPLOYING ¬.alpha.,W- BIS(DISUBSTITUTEDPHOSPHINO)HYDROCARBON\| DIGOLD (I) DIGOLD (III), DISILVER (I) AND DICOPPER (I) DERIVATIVES
CA1244764A (en) *	1984-06-04	1988-11-15	Randall K. Johnson	Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes

1985
- 1985-10-25 NL NL8502929A patent/NL8502929A/nl not_active Application Discontinuation
1986
- 1986-10-23 AT AT86201853T patent/ATE63122T1/de not_active IP Right Cessation
- 1986-10-23 DE DE8686201853T patent/DE3679045D1/de not_active Expired - Fee Related
- 1986-10-23 EP EP86201853A patent/EP0227127B1/en not_active Expired - Lifetime
- 1986-10-23 ES ES198686201853T patent/ES2039199T3/es not_active Expired - Lifetime
- 1986-10-24 PT PT83612A patent/PT83612B/pt not_active IP Right Cessation
- 1986-10-24 CA CA000521403A patent/CA1269395A/en not_active Expired - Fee Related
- 1986-10-24 HU HU903471A patent/HU203557B/hu not_active IP Right Cessation
- 1986-10-24 FI FI864327A patent/FI85861C/fi not_active IP Right Cessation
- 1986-10-24 NO NO864270A patent/NO172585B/no unknown
- 1986-10-24 YU YU181786A patent/YU45802B/sh unknown
- 1986-10-24 DK DK511786A patent/DK511786A/da not_active Application Discontinuation
- 1986-10-24 US US06/922,655 patent/US4831170A/en not_active Expired - Fee Related
- 1986-10-24 HU HU864487A patent/HU200609B/hu not_active IP Right Cessation
- 1986-10-24 IL IL80416A patent/IL80416A0/xx unknown
- 1986-10-25 CN CN86107219A patent/CN86107219A/zh active Pending
- 1986-10-25 JP JP61252843A patent/JPS62161795A/ja active Pending
- 1986-10-25 KR KR1019860008963A patent/KR870003787A/ko not_active Ceased
- 1986-10-27 ZA ZA868162A patent/ZA868162B/xx unknown
- 1986-10-27 AU AU64413/86A patent/AU601954B2/en not_active Ceased
- 1986-10-28 NZ NZ218072A patent/NZ218072A/en unknown
1991
- 1991-03-16 CN CN91101598A patent/CN1057962A/zh active Pending
- 1991-05-03 GR GR91400587T patent/GR3001910T3/el unknown
1992
- 1992-05-28 CN CN92104058A patent/CN1067430A/zh active Pending

Also Published As

Publication number	Publication date
DK511786D0 (da)	1986-10-24
EP0227127A2 (en)	1987-07-01
HU200609B (en)	1990-07-28
FI85861B (fi)	1992-02-28
AU601954B2 (en)	1990-09-27
JPS62161795A (ja)	1987-07-17
HUT44263A (en)	1988-02-29
NO864270D0 (no)	1986-10-24
CN86107219A (zh)	1987-05-27
FI85861C (fi)	1992-06-10
HU203557B (en)	1991-08-28
NZ218072A (en)	1990-12-21
US4831170A (en)	1989-05-16
DE3679045D1 (de)	1991-06-06
KR870003787A (ko)	1987-05-04
EP0227127A3 (en)	1988-09-07
AU6441386A (en)	1987-05-21
YU45802B (sh)	1992-07-20
NO864270L (no)	1987-04-27
IL80416A0 (en)	1987-01-30
FI864327A7 (fi)	1987-04-26
PT83612A (en)	1986-11-01
PT83612B (pt)	1989-05-31
EP0227127B1 (en)	1991-05-02
ATE63122T1 (de)	1991-05-15
CN1057962A (zh)	1992-01-22
FI864327A0 (fi)	1986-10-24
NL8502929A (nl)	1987-05-18
CA1269395A (en)	1990-05-22
CN1067430A (zh)	1992-12-30
YU181786A (en)	1988-02-29
HU903471D0 (en)	1990-12-28
DK511786A (da)	1987-04-26
GR3001910T3 (en)	1992-11-23
ES2039199T3 (es)	1993-09-16
ZA868162B (en)	1987-06-24

Publication	Publication Date	Title
US4562275A (en)	1985-12-31	Antitumor platinum complexes
US4200583A (en)	1980-04-29	New platinum complex
US4845124A (en)	1989-07-04	Platinum (IV) complexes
US5194645A (en)	1993-03-16	Trans-pt (iv) compounds
US5091521A (en)	1992-02-25	Cis-platinum complexes, a process for the preparation thereof, and pharmaceuticals containing these compounds
US4902797A (en)	1990-02-20	Ammine-alicyclic amine-platinum complexes and antitumor agents
US5318962A (en)	1994-06-07	Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
US4234500A (en)	1980-11-18	Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes
Bravo et al.	2019	First heterobimetallic Cu (i)–dppf complexes designed for anticancer applications: synthesis, structural characterization and cytotoxicity
KR910009823B1 (ko)	1991-11-30	백금착물(白金錯物)
GB2053212A (en)	1981-02-04	Cis-platinum(ii)amine lactate complexes
US5011959A (en)	1991-04-30	1,2-diaminocyclohexane-platinum complexes with antitumor activity
EP0115929A1 (en)	1984-08-15	Novel organic platinum complex and process for the preparation thereof
US4291027A (en)	1981-09-22	Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes
EP0227127B1 (en)	1991-05-02	Pharmaceutically active phosphino-hydrocarbon-group viii-metal complexes, antitumor compositions containing these complexes, and a process for preparing said compounds or antitumor compositions
Gill	1984	Structure activity relationship of antitumor palladium complexes
EP0232784B1 (en)	1992-12-02	(gem-heterocyclodimethanamine-n,n')platinum complexes
Barbanente et al.	2020	One‐pot synthesis of new organometallic compounds with platinum‐carbon bond
Khokhar et al.	1988	Synthesis and antitumor activity of N-substituted iminodiacetato (1, 1-bis [aminomethyl] cyclohexane) platinum (II) complexes
Sohn et al.	1994	Synthesis, structure, and antitumor activity of 1, 3-dithiol-and 1, 3-dithiolan-2-ylidenemalonatoplatinum (II) complexes
Jeragh	1979	Synthetic and kinetic studies of some transition metal complexes of macrocyclic ligands
JPS61148187A (ja)	1986-07-05	新規白金錯体
JPS6222793A (ja)	1987-01-30	新規な有機白金錯体、その製法並びに該錯体を有効成分とする抗腫瘍剤